EOTP-2025-ST-0028.R1Insights and trends in development of TEAD-YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025) [0.03%]
TEAD-YAP/TAZ抑制剂开发的洞察与趋势：2022年6月至2025年PCT专利综述
Te Fan,Zhong Yu,Aiping Xiao et al.
Te Fan et al.
Introduction: The transcription enhancer associated domain (TEAD) family has been well documented for its roles in modulating cancer development, primarily through interactions with its two co-activators: yes-associated p...
An updated patent review of small molecule glucagon receptor antagonists (2020-2024) [0.03%]
2020-2024年小分子胰高血糖素受体拮抗剂专利分析
Chunyang Wang,Liyang Lyu,Dongyang Liu et al.
Chunyang Wang et al.
Introduction: The glucagon receptor (GCGR) plays a pivotal role in diabetes management. While small molecule GCGR antagonists (GCGRAs) offer several advantages, including glycemic control, oral bioavailability, and cost-e...
Bo-Wen Wan,Cheng-Shi Jiang,Chunlin Zhuang
Bo-Wen Wan
Introduction: Mixed-spectrum kinase structural domain-like protein (MLKL), which emerged as a pivotal regulator in biomedical research, plays a critical role in necroptotic pathways. Recent advancements have underscored t...
Topoisomerase II inhibitors in oncology: an updated patent review (2016-present) [0.03%]
抗癌拓扑异构酶II抑制剂的专利回顾（2016-至今）
Eleonora Turrini,Francesca Maffei,Andrea Milelli et al.
Eleonora Turrini et al.
Introduction: Topoisomerase (topo) II inhibitors continue to represent a promising approach in anticancer therapy, although their clinical application is hampered by drug resistance and dose limiting toxicities. ...
Toll-like receptor agonists as cancer therapeutics: a patent review (2014-2024) [0.03%]
toll-like受体激动剂作为抗癌药物的专利回顾（2014-2024）
Pankaj Kumar,Zahid Bashir Zargar,Kanwaljit Chopra et al.
Pankaj Kumar et al.
Introduction: Toll-like receptors (TLRs) play key role in cancer immunotherapy by harnessing the immune system's natural response to target and fight tumors. Among various TLRs, mainly TLR3, TLR4, TLR7, TLR8, and TLR9, ha...
Bruton's tyrosine kinase (BTK) inhibitors: an updated patent review (2019-2024) [0.03%]
布鲁顿酪氨酸激酶(BTK)抑制剂专利回顾(2019-2024)更新版
Ze-Xi Cui,Sheng-Xin Yao,Yue-Xi Zhang et al.
Ze-Xi Cui et al.
Introduction: Bruton's tyrosine kinase (BTK) is a critical regulator in the pathogenesis of B-cell malignancies, inflammatory diseases, and autoimmune diseases. In recent years, BTK inhibitors have been a hot topic in dru...
Implementation and outcomes of China's drug patent linkage system: lessons from international experience [0.03%]
中国药品专利链接制度的实施及成效：国际经验借鉴
Yu Chen,Xinjuan Liu,Suju Li et al.
Yu Chen et al.
Introduction: The drug patent linkage system plays a crucial role in achieving a balance between protecting drug innovation and ensuring the accessibility of generic drugs. Currently, this system has been implemented in m...
Evaluation of the patent portfolio for helicase-primase inhibitor ABI-5366 of Assembly biosciences inc [0.03%]
评估Assembly Biosciences Inc.的HELQ抑制剂ABI-5366专利组合
Christian Gege,Gerald Kleymann
Christian Gege
Background: Helicase-primase is an interesting target for small molecule therapy of herpes simplex virus (HSV) infections. With amenamevir already approved for varicella-zoster virus and herpes simplex in Japan and with p...
Tao Liu,Mingbo Su,Yuxuan Wang et al.
Tao Liu et al.
Introduction: Checkpoint kinase 1 (CHK1), a serine/threonine kinase, plays an important role in the DNA damage response (DDR), such as cell cycle checkpoints, DNA repair, transcriptional regulation, and apoptosis inhibiti...
Traf2- and Nck-interacting kinase inhibitors: a patent review（2008 - 2024） [0.03%]
有关Traf2和Nck相互作用激酶的抑制剂专利综述（2008-2024）
Luoheng Qin,Vladimir Aladinskiy,David Gennert et al.
Luoheng Qin et al.
Introduction: Traf2- and Nck-interacting kinase (TNIK) is a crucial player in various intracellular signaling pathways, including Wnt/β-catenin, cytoskeleton organization, and immune activation. It phosphorylates several...